Back to Search Start Over

Calcitonin use in giant cell bone tumors

Authors :
M. Douik
M. Hedi Meherzi
Moez Ouertatani
K. Zehi
M. Mestiri
H. Nouri
M. Zouari
Source :
Orthopaedics & Traumatology: Surgery & Research. (5):520-526
Publisher :
Published by Elsevier Masson SAS

Abstract

Summary Introduction As osteoclast, giant cell tumors express calcitonin receptors. The aim of this paper is to assess treatment using salmon calcitonin after curettage. Material and methods We retrospectively reviewed 25 patients with giant cell tumor of the appendicular skeleton treated with a single protocol of calcitonin administration following curettage in order to assess the effectiveness of calcitonin in reducing the rate of local recurrence. Results The mean duration follow-up was 68 months. Thirteen patients (52%) had local recurrence. Eight of them were treated successfully after repeated curettage and calcitonin. Four patients had bone resection and one patient had curettage and cement filling. All patients with cavity left empty had ossified and the functional score as assessed by the MSTS score was 28.02/30. Conclusion This study suggests that the use of calcitonin as adjuvant is not effective and that filling agents are not required after curettage of giant cell tumors. Level of evidence Level 4.

Details

Language :
English
ISSN :
18770568
Issue :
5
Database :
OpenAIRE
Journal :
Orthopaedics & Traumatology: Surgery & Research
Accession number :
edsair.doi.dedup.....1dd44602dd893b5cb34862c46337c309
Full Text :
https://doi.org/10.1016/j.otsr.2011.03.019